CN113577323B - 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法 - Google Patents

基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法 Download PDF

Info

Publication number
CN113577323B
CN113577323B CN202110761531.2A CN202110761531A CN113577323B CN 113577323 B CN113577323 B CN 113577323B CN 202110761531 A CN202110761531 A CN 202110761531A CN 113577323 B CN113577323 B CN 113577323B
Authority
CN
China
Prior art keywords
minicells
minicell
pharmaceutical composition
bacterial
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110761531.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113577323A (zh
Inventor
马修·J·贾卡罗
加里·H·沃德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxiion Therapeutics LLC
Original Assignee
Vaxiion Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxiion Therapeutics LLC filed Critical Vaxiion Therapeutics LLC
Priority to CN202110761531.2A priority Critical patent/CN113577323B/zh
Publication of CN113577323A publication Critical patent/CN113577323A/zh
Application granted granted Critical
Publication of CN113577323B publication Critical patent/CN113577323B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/08—Radiation
    • A61L2/081—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
CN202110761531.2A 2015-08-04 2016-08-03 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法 Active CN113577323B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110761531.2A CN113577323B (zh) 2015-08-04 2016-08-03 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562200903P 2015-08-04 2015-08-04
US62/200,903 2015-08-04
CN201680053686.8A CN108348624B (zh) 2015-08-04 2016-08-03 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法
PCT/US2016/045400 WO2017024059A1 (en) 2015-08-04 2016-08-03 Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use
CN202110761531.2A CN113577323B (zh) 2015-08-04 2016-08-03 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680053686.8A Division CN108348624B (zh) 2015-08-04 2016-08-03 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法

Publications (2)

Publication Number Publication Date
CN113577323A CN113577323A (zh) 2021-11-02
CN113577323B true CN113577323B (zh) 2024-02-20

Family

ID=57943608

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110761531.2A Active CN113577323B (zh) 2015-08-04 2016-08-03 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法
CN201680053686.8A Active CN108348624B (zh) 2015-08-04 2016-08-03 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680053686.8A Active CN108348624B (zh) 2015-08-04 2016-08-03 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法

Country Status (7)

Country Link
US (3) US10124024B2 (https=)
EP (1) EP3331575A4 (https=)
JP (2) JP6824960B2 (https=)
KR (2) KR102687638B1 (https=)
CN (2) CN113577323B (https=)
AU (1) AU2016301302B2 (https=)
WO (1) WO2017024059A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11167008B2 (en) 2016-11-23 2021-11-09 Vaxiion Therapeutics, Llc Immunomodulatory and oncolytic minicells and methods of use
AU2018256925B2 (en) 2017-04-28 2024-11-21 Agrospheres, Inc. Compositions and methods for the encapsulation and scalable delivery of agrochemicals
US11624061B2 (en) 2017-04-28 2023-04-11 Agrospheres, Inc. Compositions and methods for enzyme immobilization
BR112020005803A2 (pt) 2017-09-25 2020-12-01 Agrospheres, Inc. composições e métodos para produção e administração moduláveis de produtos biológicos
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN110514772A (zh) * 2019-08-09 2019-11-29 中国医学科学院基础医学研究所 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
EP4061802A4 (en) * 2019-12-23 2024-01-24 Agrospheres, Inc. Compositions and methods for enhanced uptake of active ingredients for animal health and nutrition
MX2022014531A (es) * 2020-05-21 2023-03-03 Coherus Biosciences Inc Sistemas y metodos para producir dispositivos de inyeccion esteriles.
JP2024504510A (ja) * 2020-12-11 2024-01-31 アグロスフィアズ，インコーポレイティド ミニセルの拡張可能な大量生産のためのバイオプロセスシステムおよび方法
WO2022215495A1 (ja) * 2021-04-08 2022-10-13 株式会社カネカ 環状リポペプチド化合物のバイオバーデンの低減方法
CN117618602A (zh) * 2023-12-18 2024-03-01 苏州尔生生物医药有限公司 一种负载癌细胞裂解物组分的癌症粒子疫苗的终端灭菌方法及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
CN102349978A (zh) * 2011-10-27 2012-02-15 天津中新药业集团股份有限公司达仁堂制药厂 生血丸在制备预防低剂量电离辐射致细胞损伤药物中的应用
WO2012112696A1 (en) * 2011-02-15 2012-08-23 Vaxiion Therapeutics, Inc. Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
WO2014055682A1 (en) * 2012-10-02 2014-04-10 Vaxiion Therapeutics, Inc. Immunomodulatory minicells and methods of use
CN104027809A (zh) * 2007-04-08 2014-09-10 免疫之光有限责任公司 治疗细胞增殖性疾病的方法和系统

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58131920A (ja) 1982-01-29 1983-08-06 Nisshin Flour Milling Co Ltd 鶏の大腸菌症の予防法
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
WO1999059643A2 (en) 1998-05-20 1999-11-25 Sdg, Inc. Liposomal delivery complex
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030166099A1 (en) 2001-06-05 2003-09-04 Sabbadini Roger A. Minicells comprising membrane proteins
US20030207833A1 (en) 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
ATE502300T1 (de) 2002-12-26 2011-04-15 Nitto Boseki Co Ltd Immunoassay-verfahren
CA2516942A1 (en) * 2003-02-04 2004-08-19 Mcmaster University Use of quinazoline derivatives or other compounds for inhibiting dihydrofolate reduxtase; screening assay for the identification of novel therapeutics and their cellular targets
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
CN101954095B (zh) 2003-12-09 2013-03-13 基因分子传递股份有限公司 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞
WO2005058333A1 (de) * 2003-12-18 2005-06-30 Owen Holding Ltd Methode zur gewinnung eines biologisch aktiven mit elektroschock behandelten blutserums und seine verwendung
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
EP1718338B1 (en) 2004-02-02 2015-05-06 EnGeneIC Molecular Delivery Pty Ltd. Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
WO2006055024A2 (en) 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicells as vaccines
EP2386640B1 (en) 2004-08-26 2015-01-28 EnGeneIC Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
WO2009012493A2 (en) 2007-07-19 2009-01-22 The Board Of Regents Of The University Of Oklahoma H-antigen binding polypeptides and methods of use
US8236538B2 (en) * 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
EP3020811A1 (en) 2008-06-25 2016-05-18 Vaxiion Therapeutics, LLC Regulated genetic suicide mechanism compositions and methods
WO2010057009A1 (en) 2008-11-14 2010-05-20 Cequent Pharmaceuticals, Inc. E. coli mediated gene silencing of beta-catenin
US11167008B2 (en) * 2016-11-23 2021-11-09 Vaxiion Therapeutics, Llc Immunomodulatory and oncolytic minicells and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
CN104027809A (zh) * 2007-04-08 2014-09-10 免疫之光有限责任公司 治疗细胞增殖性疾病的方法和系统
WO2012112696A1 (en) * 2011-02-15 2012-08-23 Vaxiion Therapeutics, Inc. Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
CN102349978A (zh) * 2011-10-27 2012-02-15 天津中新药业集团股份有限公司达仁堂制药厂 生血丸在制备预防低剂量电离辐射致细胞损伤药物中的应用
WO2014055682A1 (en) * 2012-10-02 2014-04-10 Vaxiion Therapeutics, Inc. Immunomodulatory minicells and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《军事医学》编辑委员会.电离辐射.《中国医学百科全书 军事医学》.上海科学技术出版社,1995,(第1版),第820-821页. *
何小维 等.海藻糖.《碳水化合物功能材料》.中国轻工业出版社,2007,(第1版),第372-373页. *

Also Published As

Publication number Publication date
US20180153942A1 (en) 2018-06-07
KR102558941B1 (ko) 2023-07-21
AU2016301302B2 (en) 2023-01-12
JP2018522036A (ja) 2018-08-09
US20230321159A1 (en) 2023-10-12
WO2017024059A8 (en) 2017-06-29
CN108348624A (zh) 2018-07-31
EP3331575A1 (en) 2018-06-13
CN108348624B (zh) 2021-07-27
KR20230111275A (ko) 2023-07-25
US20190282629A1 (en) 2019-09-19
JP2021059600A (ja) 2021-04-15
AU2016301302A1 (en) 2018-03-08
KR102687638B1 (ko) 2024-07-22
JP7568519B2 (ja) 2024-10-16
US11564953B2 (en) 2023-01-31
US10124024B2 (en) 2018-11-13
EP3331575A4 (en) 2019-03-27
KR20180056642A (ko) 2018-05-29
US12427172B2 (en) 2025-09-30
JP6824960B2 (ja) 2021-02-03
CN113577323A (zh) 2021-11-02
WO2017024059A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
CN113577323B (zh) 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法
US10919942B2 (en) Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
ES2828092T3 (es) Minicélulas inmunomoduladoras y métodos de uso
US20220054585A1 (en) Immunomodulatory & oncolytic minicells and methods of use
US20250339518A1 (en) Dual sting/rig-i agonist oncolytic minicells as in situ immunization agents and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant